Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).
Christopher S. Seet, MD, PhD
Advertisement
Articles by Christopher S. Seet, MD, PhD
Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA Health, discusses the need for long-term outcome data pertaining to treatment discontinuation in chronic myeloid leukemia (CML).
Advertisement
Latest Updated Articles
Dr. Seet on the Need for Long-Term Outcome Data Regarding Treatment Discontinuation in CMLPublished: August 28th 2019 | Updated:
Dr. Seet on Aspects of Treatment Discontinuation in CMLPublished: September 18th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
2
FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy
3
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
4
Leveraging AI for Optimal Clinical Trial Design in Oncology
5